HSA
BIOC

Hussman Strategic Advisors’s Biocept, Inc. BIOC Stock Holding History

Hussman Strategic Advisors’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,400
Closed -$302K – 363
2021
Q2 		$302K Hold
2,400
– – 0.06% 296
2021
Q1 		$366K Buy
2,400
+2,283
+1,951% +$414K 0.08% 285
2020
Q4 		$16K Sell
117
-2,666
-96% -$380K ﹤0.01% 269
2020
Q3 		$368K Buy
+2,783
New +$562K 0.1% 230

Other funds holding BIOC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hussman Strategic Advisors's BIOC Position: Q3 2021 in Review

Hussman Strategic Advisors sold out of Biocept, Inc. (BIOC) in Q3 2021, closing a stake of 2,400 shares — an estimated $302K sold.

Hussman Strategic Advisors first reported a position in BIOC in Q3 2020 and held it in 4 quarters. The position peaked at $368K in Q3 2020. 26 funds tracked by Wall St. Rank hold BIOC as of Q3 2021.

  • Hussman Strategic Advisors reported no remaining Biocept, Inc. position as of Q3 2021 after selling out during the quarter.
  • Hussman Strategic Advisors sold 2,400 Biocept, Inc. shares in Q3 2021, an estimated $302K.
  • Hussman Strategic Advisors first reported a position in Biocept, Inc. in Q3 2020 and held it in 4 quarters.
  • Hussman Strategic Advisors's Biocept, Inc. position peaked at $368K in Q3 2020.
  • 26 funds tracked by Wall St. Rank held Biocept, Inc. as of Q3 2021.

Based on Hussman Strategic Advisors's 13F filing for Q3 2021, filed 1 Nov 2021.